title: A role for antiangiogenic therapy in breast cancer.
abstract: The success of the angiogenesis inhibitor bevacizumab, the vascular endothelial growth factor antagonist that was recently shown to significantly improve the survival of patients with metastatic colon cancer when administered in combination with conventional chemotherapy, has provided proof of principle in clinical trials that antiangiogenesis can be an important strategy in the treatment of cancer. This report reviews the contemporary therapeutic approaches for breast cancer, the essential role that angiogenesis plays in the initiation and progression of this disease, and the strategies that should be considered to make antiangiogenic therapy a successful component of breast cancer treatment.
authors.affiliation: Vascular Biology Program, Children's Hospital, Enders 1009, 320 Longwood Avenue, Boston, MA 02115, USA. marsha.moses@tch.harvard.edu
authors.forename: Marsha A
authors.initials: MA
authors.lastname: Moses
authors.forename: Jay
authors.initials: J
authors.lastname: Harper
authors.forename: Cecilia A
authors.initials: CA
authors.lastname: Fernández
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000187:drug effects; D005260:Female; D006801:Humans; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D011379:Prognosis; D016387:Women's Health
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab